Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 92 people in total across four groups. Most participants (40 and 44 people respectively) were already tolerating tube feeding at the start and were given either a placebo followed by camicinal, or camicinal followed by metoclopramide (another medicine). A smaller group of 8 people who were not tolerating tube feeding were given either camicinal or metoclopramide. The trial was measuring how much of a person's prescribed tube-feeding nutrition they actually received, and was comparing a drug called camicinal (50 mg) against a placebo (a dummy treatment with no active ingredient). The reported data shows that, for the main measurement — the average percentage of the prescribed tube-feed volume delivered before any feeding intolerance developed — participants in the camicinal group received an average of 76.6% of their prescribed volume, compared with 67.7% in the placebo group (in the full group of enrolled participants). In a separate analysis limited to participants who followed the study protocol most closely, both groups received around 76.6% and 74.4% respectively. For the secondary measurements, the camicinal group was reported to have received an average of 76.7% of their prescribed calories and 76.3% of their prescribed protein, compared with 67.8% and 69.8% respectively in the placebo group. The reported data also shows that the estimated time to reaching 80% of prescribed calories was 2 days in the camicinal group and 1 day in the placebo group. Regarding adverse events (unexpected medical occurrences during the trial), the numbers of participants who experienced these were reported across each group, but no safety conclusions are drawn here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Gastroparesis Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 85 years old (male or female)
- You were admitted to the participating intensive care unit (ICU) within the last 48 hours
- You are on a breathing machine (ventilator) through a tube in your throat
- You are already receiving, or are planned to receive, nutrition through a feeding tube
- You have at least one of the following conditions:
- Your heart and blood pressure need support from special medications called vasopressors for 2 or more hours
- You have multiple serious injuries with a combined injury score of 15 points or more
- You have a brain injury (from trauma or another cause) and scored 12 or lower on a standard brain function test before being sedated
Who may not be able to join:
- You are not expected to survive or remain in the ICU for at least 48 hours
- You have an active liver infection (such as hepatitis B or C) or severe long-term liver disease
- Your liver blood test results are significantly above the normal range (confirm with trial site for specific values)
- You have received certain stomach-motility medications (such as erythromycin, metoclopramide, or domperidone) in the last 12 hours
- Your heart's electrical activity (measured by an ECG) shows a reading above a certain level (confirm with trial site)
- You are taking certain strong medications that affect how the body processes drugs (known as strong CYP3A4 inhibitors)
- Your kidneys are not working well enough, or you are on dialysis or a similar kidney treatment
- You have had major surgery on your stomach or food pipe during this hospital stay
- You have a complete blockage or hole in your bowel, or any other reason you cannot receive tube feeding
- You have a gastric pacemaker (a device implanted in your stomach)
- You are pregnant or breastfeeding
- You have had a previous allergic reaction to any of the medications used in this study
- You are already taking part in another clinical trial involving an experimental drug or treatment
- You have already been enrolled in this same study before
- You were admitted to the ICU because of a drug overdose (whether accidental or deliberate)
- You have an untreated tumour of the adrenal gland (pheochromocytoma)
- You have a history of epilepsy or seizures and are currently on anti-epilepsy medication for an ongoing seizure condition (confirm specific details with trial site)
- You are taking medications known to cause involuntary muscle movements or stiffness (extrapyramidal reactions)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: GSK Clinical Trials, GlaxoSmithKline
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Average Percentage Goal Volume Delivered Prior to Development of Intolerance for ITT Population; Average Percentage Goal Volume Delivered Prior to Development of Intolerance for PP Population
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.